LY-M003

N/A

Report date: 2026/02/09 20:01:27

Base Information

Drug NameLY-M003
Drug Alias NameLY-M003
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionCopper-transporting ATPase replacementsGene transference
TargetsCopper-transporting ATPase
Therapy Area/IndicationsMetabolic DiseasesHepatolenticular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLingyi Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFirst Affiliated Hospital Of Zhejiang UniversityLingyi Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic DiseasesHepatolenticular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A